Oura is preparing to add blood pressure monitoring to its latest smart rings, pushing the category closer to features once reserved for specialized wearables. While consumer devices that are medically certified for blood pressure remain rare—the Huawei Watch D and Watch D2 still lead that pack—mainstream brands have been racing to deliver some form of BP tracking. Oura now joins that conversation with plans for the Oura Ring 3 and Oura Ring 4.
The company says the feature will roll out only after it secures the necessary regulatory approvals. Ahead of that, an early access program will open soon through Oura Labs, giving eligible users a preview of how the technology will work on their rings.
There are important caveats. Early access will be limited to users in the United States who are at least 22 years old. Those with pacemakers are excluded, and additional eligibility requirements may apply. Oura recommends checking the company’s official channels for the latest details.
Oura’s approach relies on the rings’ optical PPG sensors to interpret blood pressure trends. Unlike some smartwatch implementations, it won’t require calibration with a traditional cuff-based monitor. The trade-off is that the rings won’t display precise systolic and diastolic values. Instead, users should expect trend-based insights and directional changes over time, rather than clinical-grade measurements.
This strategy mirrors what we’ve seen across the broader wearables market: growing interest in blood pressure tracking, often with limitations or paid access. Some competitors advertise BP capabilities with their own restrictions, while others place the feature behind a subscription paywall. Oura’s move signals that smart rings are becoming serious contenders for health and wellness tracking, even if they’re not intended to replace medical devices.
If you’re an Oura Ring 3 or Oura Ring 4 owner, keep an eye out for the Oura Labs invitation. For now, consider the upcoming blood pressure tool a wellness feature designed to surface useful trends, not a substitute for a clinical monitor or professional advice. The full release will depend on regulatory clearance, but early access should offer a clear preview of what’s coming.
